Dyadic International (NASDAQ:DYAI) Major Shareholder Francisco Trust Under Agreemen Sells 15,000 Shares

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 15,000 shares of the firm’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $2.01, for a total value of $30,150.00. Following the completion of the sale, the insider directly owned 3,375,664 shares in the company, valued at approximately $6,785,084.64. This represents a 0.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Dyadic International Trading Up 10.1%

Shares of DYAI opened at $1.06 on Tuesday. The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.42 and a current ratio of 2.42. Dyadic International Inc. has a 52-week low of $0.65 and a 52-week high of $1.35. The firm has a market cap of $38.81 million, a price-to-earnings ratio of -4.70 and a beta of 1.15. The business’s fifty day moving average is $0.77 and its 200-day moving average is $0.83.

Dyadic International (NASDAQ:DYAI) last announced its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The business had revenue of $1.11 million for the quarter, compared to the consensus estimate of $0.90 million. Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%. Equities analysts anticipate that Dyadic International Inc. will post 0.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Bank of America Corp DE boosted its holdings in shares of Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 26,965 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new position in Dyadic International in the 3rd quarter worth about $190,000. Marathon Capital Management bought a new position in Dyadic International in the third quarter valued at about $41,000. Apis Capital Advisors LLC bought a new position in Dyadic International in the third quarter valued at about $1,817,000. Finally, Geode Capital Management LLC boosted its stake in shares of Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 36,266 shares in the last quarter. 27.95% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dyadic International in a report on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $3.00.

Key Dyadic International News

Here are the key news stories impacting Dyadic International this week:

• Positive Sentiment: Dyadic said global collaborations continue to validate its C1 protein-expression platform and expand its commercial opportunity, reinforcing the investment case around its core biotechnology technology. Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential
• Neutral Sentiment: The company’s latest reported quarterly results were mixed, with revenue beating expectations but earnings per share missing estimates, leaving investors focused on future commercialization progress rather than near-term profitability.
• Negative Sentiment: Major shareholder Francisco Trust Under Agreemen disclosed additional stock sales, adding to recent insider selling that may create some caution around the stock’s near-term momentum.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.